A Philadelphia jury has awarded $1.75 million to a plaintiff who alleged that taking the antipsychotic drug Risperdal caused gynecomastia, a condition in which boys grow excessive breast tissue.

The jury handed up the verdict in Murray v. Janssen Pharmaceuticals on Monday following about two weeks of trial and two-and-a-half hours of deliberations. The jury determined that Janssen Pharmaceuticals, which made the drug, failed to warn health care providers about gynecomastia as a risk of taking the drug, and the failure to warn caused plaintiff Nicholas Murray's injuries.

“I think the jury was convinced that Janssen hid data from the [U.S. Food and Drug Administration] and the doctors, and I think that the jury's verdict shows that, when children are involved, juries aren't going to let drug companies get away with hiding the data,” said Murray's attorney, Jason Itkin of Arnold & Itkin. “I think it sends a message to Janssen. … We're going to try these cases and we expect the verdicts to get better and better.”